THERAVANCE INC
			Symbol			THRX

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Theravance Reports Third Quarter 2009 Financial Results

2009-10-27 16:05 ET - News Release

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 10/27/09

Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended September 30, 2009. Net loss for the third quarter of 2009 was $22.2 million compared with $20.9 million for the same period in 2008. Net loss per share was $0.35 for the third quarter of 2009 compared with a net loss per share of $0.34 for the same period in 2008.

"In the third quarter, Theravance achieved significant milestones with the approval of VIBATIV(TM) in the United States and in Canada," said Rick E Winningham, Chief Executive Officer. "VIBATIV was discovered and developed by Theravance and is our first approved medicine. We believe that VIBATIV will provide an important new option for physicians treating complicated skin and skin structure infections caused by Gram-positive bacteria including MRSA. In the Horizon program, GlaxoSmithKline (GSK) and Theravance announced the initiation of the large Phase 3 program in COPD this morning and noted our full commitment to the development of the asthma program. We are excited about the accomplishments of Theravance and will continue to work diligently to advance our programs."

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.